Table 1.
Ocular Pharmacokinetic Data from Cynomolgus Monkeys Treated Systemically with Oral Dosing of GW782415X
| Ocular region | Regimen |
||
|---|---|---|---|
| Placebo | GW782415X 9 mg/kg per day |
GW782415X 60 mg/kg per day |
|
| Cornea | BLQ | BLQ | 228 ± 94.7 ng/g |
| Aqueous humor | BLQ | 12.4 ± 2.12 ng/mL | 127 ± 36.9 ng/mL |
| Iris/ciliary body | BLQ | 8460 ± 2510 ng/g | 60,800 ± 14,500 ng/g |
| Retina (punch) | BLQ | 253 ± 343 ng/g | 1370 ± 495 ng/g |
| Retina (remaining) | BLQ | 735 ± 453 ng/g | 4670 ± 1690 ng/g |
| Choroid (punch) | BLQ | 51,300 ± 21,100 ng/g | 186,000 ± 53,100 ng/g |
| Choroid (remaining) | BLQ | 47,800 ± 19,900 ng/g | 281,000 ± 114,000 ng/g |
| Vitreous humor | BLQ | 5.93 ± 6.88 ng/mL | 92.1 ± 10.8 ng/mL |
Ocular tissue levels were isolated 29 days after thrice-daily oral administration of the CCR3 antagonist. Data are expressed as means ± SD. n = 4 eyes per dose regimen.
BLQ, below limit of quantitation (10 ng/g tissue).